Abstract |
Large-scale, unbiased combinatorial drug screening has been used to identify effective genotype-selective therapeutic combinations that show promising activity in preclinical models of mutant BRAF andRAS melanoma that are resistant to the clinical BRAF inhibitor vemurafenib.
|
Authors | Bissan Al-Lazikani, Paul Workman |
Journal | Cancer discovery
(Cancer Discov)
Vol. 3
Issue 1
Pg. 14-9
(Jan 2013)
ISSN: 2159-8290 [Electronic] United States |
PMID | 23319765
(Publication Type: Journal Article, Research Support, Non-U.S. Gov't, Comment)
|
Chemical References |
- Antineoplastic Agents
- BRAF protein, human
- Proto-Oncogene Proteins B-raf
- ras Proteins
|
Topics |
- Animals
- Antineoplastic Agents
(administration & dosage)
- Humans
- Melanoma
(drug therapy)
- Proto-Oncogene Proteins B-raf
(genetics)
- ras Proteins
(genetics)
|